Skip to main content

Advertisement

Log in

High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies

  • Hepatic and Pancreatic Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Radiofrequency ablation (RFA) is a recently developed treatment for hepatocellular carcinoma (HCC). Thus far, the prognostic impact of tumor biomarkers has not been evaluated in this treatment. High serum level of vascular endothelial growth factor (VEGF) has been shown to predict microscopic vascular invasion and metastasis in HCC. This study investigated the prognostic significance of pre-treatment serum VEGF level in patients with HCC undergoing RFA treatment.

Methods

Serum VEGF levels were measured using enzyme-linked immunosorbent assay in 120 patients with HCC undergoing RFA, and in 15 healthy controls. Serum VEGF levels were correlated with clinicopathological features of the HCC patients. The prognostic significance of serum VEGF levels was assessed by univariate and multivariate analyses.

Results

The median serum VEGF level in the HCC patients was 240 pg/mL (range 17–1162), significantly higher than that of healthy controls (p = .024). The serum VEGF levels were significantly correlated with platelet counts (r = .487, p < .001) but not other clinicopathological features. Patients with serum VEGF level > 240 pg/mL had worse overall and recurrence-free survival compared with those with serum VEGF level > 240 pg/mL (p = .005 and .002, respectively). By multivariate analysis, serum VEGF level was a significant prognostic factor of both overall and recurrence-free survival.

Conclusions

High pre-treatment serum VEGF levels predict poor prognosis after RFA of HCC. This study highlights the importance of tumor biomarker as a prognostic predictor in ablative therapy for HCC, which has an intrinsic problem of unavailability of histopathological prognostic features.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

FIG. 1.
FIG. 2.
FIG. 3.

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153–6

    Article  PubMed  CAS  Google Scholar 

  2. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229:790–9

    Article  PubMed  CAS  Google Scholar 

  3. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001; 234:63–70

    Article  PubMed  CAS  Google Scholar 

  4. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1):S268–76

    Article  PubMed  Google Scholar 

  5. Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon’s perspective. Ann Surg 2002; 235:466–86

    Article  PubMed  Google Scholar 

  6. Poon RT, Ng KK, Lam CM, et al. Radiofrequency ablation for subcapsular hepatocellular carcinoma. Ann Surg Oncol 2004; 11:281–9

    Article  PubMed  Google Scholar 

  7. Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210:655–61

    PubMed  CAS  Google Scholar 

  8. Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000; 232:381–91

    Article  PubMed  CAS  Google Scholar 

  9. Raut CP, Izzo F, Marra P, et al. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol 2005; 12:616–28

    Article  PubMed  Google Scholar 

  10. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005; 234:961–7

    Article  PubMed  Google Scholar 

  11. Machi J, Bueno RS, Wong LL. Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma. World J Surg 2005; 29:1364–73

    Article  PubMed  Google Scholar 

  12. Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004; 127:1714–23

    Article  PubMed  Google Scholar 

  13. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129:122–30

    Article  PubMed  Google Scholar 

  14. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243:321–8

    Article  PubMed  Google Scholar 

  15. Ng KK, Poon RT. Radiofrequency ablation for malignant liver tumor. Surg Oncol 2005; 14:41–52

    Article  PubMed  Google Scholar 

  16. Vivarelli M, Guglielmi A, Ruzzenente A, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004; 240:102–7

    Article  PubMed  Google Scholar 

  17. Kim YS, Rhim H, Cho OK, et al. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol 2006; 59:432–41

    Article  PubMed  CAS  Google Scholar 

  18. Xu HX, Lu MD, Xie XY, et al. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients. Clin Radiol 2005; 60:1018–25

    Article  PubMed  Google Scholar 

  19. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232:10–24

    Article  PubMed  CAS  Google Scholar 

  20. Salizzoni M, Romagnoli R, Lupo F, et al. Microscopic vascular invasion detected by anti-CD34 immunohistochemistry as a predictor of recurrence of hepatocellular carcinoma after liver transplantation. Transplantation 2003; 76:844–8

    Article  PubMed  Google Scholar 

  21. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33:1080–6

    Article  PubMed  CAS  Google Scholar 

  22. Torimura T, Sata M, Ueno T, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998; 29:986–91

    Article  PubMed  CAS  Google Scholar 

  23. Li XM, Tang ZY, Zhou G, et al. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 1998; 17:13–7

    PubMed  Google Scholar 

  24. Huang GW, Yang LY, Lu WQ. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol 2005; 11:1705–8

    PubMed  CAS  Google Scholar 

  25. Poon RT, Ng IO, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001; 233:227–35

    Article  PubMed  CAS  Google Scholar 

  26. Poon RT, Ho JW, Tong CS, et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91:1354–60

    Article  PubMed  CAS  Google Scholar 

  27. Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003; 10:355–62

    Article  PubMed  Google Scholar 

  28. Poon RT, Lau C, Yu WC, et al. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 2004; 11:1077–84

    PubMed  CAS  Google Scholar 

  29. Li X, Feng GS, Zheng CS, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10:2878–82

    PubMed  CAS  Google Scholar 

  30. Poon RT, Ng KK, Lam CM, et al. Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg 2004; 239:441–9

    Article  PubMed  Google Scholar 

  31. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236:37–42

    Article  PubMed  Google Scholar 

  32. Cooper BC, Ritchie JM, Broghammer CL, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 2002; 8:3193–7

    PubMed  CAS  Google Scholar 

  33. Edmonson H, Steiner PE. Primary carcinoma of the liver: a study of 100 among 48,900 necropsies. Cancer 1954; 7:462–503

    Article  Google Scholar 

  34. Teknos TN, Cox C, Yoo S, et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 2002; 24:1004–11

    Article  PubMed  Google Scholar 

  35. Liotta LA, Stracke ML. Tumor invasion and metastases: biochemical mechanisms. Cancer Treat Res 1988; 40:223–38

    PubMed  CAS  Google Scholar 

  36. Smith BD, Smith GL, Carter D, et al. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 2000; 18:2046–52

    PubMed  CAS  Google Scholar 

  37. Byrnes K, White S, Chu Q, et al. High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 2006; 243:684–90

    Article  PubMed  Google Scholar 

  38. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19:1207–25

    PubMed  CAS  Google Scholar 

  39. Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006; 242:151–67

    Article  PubMed  CAS  Google Scholar 

  40. Zhang ZL, Liu ZS, Sun Q. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 2006; 12:4241–5

    PubMed  CAS  Google Scholar 

  41. Liu Y, Poon RT, Li Q, et al. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2005; 65:3691–9

    Article  PubMed  CAS  Google Scholar 

  42. Poon RT, Lau CP, Cheung ST, et al. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003; 63:3121–6

    PubMed  CAS  Google Scholar 

  43. Frank RE, Saclarides TJ, Leurgans S, et al. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 1995; 222:695–9

    Article  PubMed  CAS  Google Scholar 

  44. Olivarez D, Ulbright T, DeRiese W, et al. Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res 1994; 54:2800–2

    PubMed  CAS  Google Scholar 

  45. Graham CH, Rivers J, Kerbel RS, et al. Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am J Pathol 1994; 145:510–4

    PubMed  CAS  Google Scholar 

  46. Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002; 20:1775–85

    Article  PubMed  Google Scholar 

  47. Sun HC, Tang ZY, Li XM, et al. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol 1999; 125:419–26

    Article  PubMed  CAS  Google Scholar 

  48. Tang Z, Qin L, Wang X, et al. Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J (Engl) 1998; 111:313–8

    CAS  Google Scholar 

  49. Berber E, Rogers S, Siperstein A. Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer: a prospective study. Surg Endosc 2005; 19:710–4

    Article  PubMed  CAS  Google Scholar 

  50. Chung IK, Park MJ, Kwon KT, et al. [The factors related to the prognosis of solitary hepatocellular carcinoma after radiofrequency ablation]. Korean J Hepatol 2005; 11:371–80

    PubMed  Google Scholar 

  51. Jinno K, Tanimizu M, Hyodo I, et al. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 1998; 33:376–82

    Article  PubMed  CAS  Google Scholar 

  52. el-Houseini ME, Mohammed MS, Elshemey WM, et al. Enhanced detection of hepatocellular carcinoma. Cancer Control 2005; 12:248–53

    PubMed  Google Scholar 

  53. Huo TI, Wu JC, Hsia CY, et al. Hepatitis C virus infection is a risk factor for tumor recurrence after resection of small hepatocellular carcinomas. World J Surg 2004; 28:787–91

    Article  PubMed  Google Scholar 

  54. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004; 130:497–513

    Article  PubMed  CAS  Google Scholar 

  55. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89:500–7

    Article  PubMed  CAS  Google Scholar 

  56. Li XM, Tang ZY, Qin LX, et al. Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 1999; 18:511–7

    PubMed  CAS  Google Scholar 

  57. Zhao J, Hu J, Cai J, et al. Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma. Chin Med J (Engl) 2003; 116:772–6

    CAS  Google Scholar 

  58. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11:1086–92

    Article  PubMed  Google Scholar 

  59. George ML, Eccles SA, Tutton MG, et al. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000; 6:3147–52

    PubMed  CAS  Google Scholar 

  60. Li B, Sharpe EE, Maupin AB, et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 2006; 20:1495–7

    Article  PubMed  CAS  Google Scholar 

  61. Moore MA, Hattori K, Heissig B, et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 2001; 938:36–45

    Article  PubMed  CAS  Google Scholar 

  62. Ho JW, Pang RW, Lau C, et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 2006; 44:836–43

    Article  PubMed  CAS  Google Scholar 

  63. Gasparini G, Longo R, Toi M, Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2005; 2:562–77

    Article  PubMed  CAS  Google Scholar 

  64. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:1898–903

    Article  PubMed  CAS  Google Scholar 

Download references

ACKNOWLEDGMENT

Supported by a Competitive Earmarked Research Grant from Research Grant Council of Hong Kong (HKU7337/02M).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ronnie T. P. Poon MS, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poon, R.T.P., Lau, C., Pang, R. et al. High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies. Ann Surg Oncol 14, 1835–1845 (2007). https://doi.org/10.1245/s10434-007-9366-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-007-9366-z

Keywords

Navigation